日本語 
I feel that four Japanese researchers have earned the 2026 Lasker Awards showing Japan’s ongoing impact in biomedical research and pharmaceutical innovation. These awards cover medical science and drug development and they connect decades of academic study with medicines that help patients around the globe.
The 2026 awards honor University of Tsukuba professor Masashi Yanagisawa and three researchers from Chugai Pharmaceutical. Kunihiro Hattori, Tomoyuki Igawa and Takehisa Kitazawa. Yanagisawa shared the Lasker Basic Medical Research Award with Stanford University professor Emmanuel Mignot for their work on orexin and narcolepsy. The three Chugai researchers received the Lasker-DeBakey Clinical Medical Research Award for their role in creating Hemlibra, a medicine for hemophilia A.
The awards are very important because they show two routes in Japan’s medical innovation system: long‑term basic research that reveals biological mechanisms and industry‑led development that turns scientific findings into real therapies.
Orexin Research Connects Basic Science to New Treatments
I think Yanagisawa’s work has greatly affected how we understand sleep and wakefulness. In 1998 he found orexin, a brain peptide that helps keep us awake. Later work with Mignot showed that not having orexin is closely linked to narcolepsy.
Narcolepsy is a sleep disorder that causes extreme daytime sleepiness and other symptoms that can badly disturb everyday life.
The recognition shows the journey that biomedical innovation can take. A discovery made years ago can later become the basis for new ways to diagnose and treat.
I believe for Japan that link is crucial. Universities and research centers still bring forward discoveries in fields like neuroscience, genetics, immunology and molecular biology.. Turning those discoveries into medicines that people can buy needs teamwork between scientists, drug companies, regulators and doctors.
Chugai Researchers Recognized for Hemlibra
The Japanese achievement comes from Chugai Pharmaceutical. Kunihiro Hattori, Tomoyuki Igawa and Takehisa Kitazawa were honored for creating Hemlibra called emicizumab, which helps people with hemophilia A.
The medicine uses a bispecific antibody method to restore blood‑clotting activity in patients who do not have enough factor VIII. It offers an option instead of standard replacement therapy and can lower how often patients need treatment.
I think the award matters for Japan’s drug industry because it shows how platform technologies that tackle medical problems are vital. Antibody engineering, protein design and advanced biologics production are growing fields of competition, in the drug market.
The recognition also demonstrates how Japanese drugmakers can add to medicine by mixing deep biological knowledge with advanced therapy development.
Implications for Japans Life Sciences Industry
The four awards could help Japan become more important in the life sciences field at a time when new medicines are being created in many different countries.
Japan is good at finding drugs working with biology doing medical studies and creating personalized treatments.. The country also has problems like needing better places for new businesses to grow, better ways to move new ideas from schools to companies and more people and money moving between schools and industry.
The Lasker award shows what can happen when basic research is kept going for a time and then used to create real treatments for patients.
For drug companies in Japan this could help them see the value of taking chances on research that might not pay off quickly. For schools and research places it shows that discoveries made years ago can have a big effect around the world.
Technology Is Becoming More Important to Medical Research
The wins also show that technology is playing a part in new medical research.
Advanced computers, looking at genes machines that do lab work, pictures of the body working with data and smart programs are being used more and more in finding drugs and testing them. These tools can help scientists understand living systems find places to treat diseases and make new medicines faster.
Also Read: AI Drug Discovery in Japan: How Machine Learning Is Accelerating Pharmaceutical Research
Japans technology companies therefore have chances to work with drug makers and research groups. The place where computer programs, biology and health care meet could be a source of new ideas in the future.
The Lasker awards do not mean Japan will always be the best in every part of technology.. The recognition of four Japanese scientists shows that the country is still making research that matters around the world.
For Japans health care and technology businesses the main idea is clear: big medical discoveries usually need people to keep putting money into science for a time. Taking what schools find and connecting it to drug making, computer tools and real patients could be very important for Japan to stay strong, in the life sciences business.
English